1. Home
  2. GKOS vs NEA Comparison

GKOS vs NEA Comparison

Compare GKOS & NEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$116.08

Market Cap

5.4B

Sector

Health Care

ML Signal

HOLD

Logo Nuveen AMT-Free Quality Municipal Income Fund of Beneficial Interest Par Value $.01

NEA

Nuveen AMT-Free Quality Municipal Income Fund of Beneficial Interest Par Value $.01

HOLD

Current Price

$11.57

Market Cap

3.5B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
GKOS
NEA
Founded
1998
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
5.4B
3.5B
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
GKOS
NEA
Price
$116.08
$11.57
Analyst Decision
Strong Buy
Analyst Count
13
0
Target Price
$125.54
N/A
AVG Volume (30 Days)
848.0K
803.4K
Earning Date
10-29-2025
01-01-0001
Dividend Yield
N/A
4.23%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$469,820,000.00
N/A
Revenue This Year
$31.15
N/A
Revenue Next Year
$24.15
N/A
P/E Ratio
N/A
N/A
Revenue Growth
30.38
N/A
52 Week Low
$73.16
$9.20
52 Week High
$163.71
$11.37

Technical Indicators

Market Signals
Indicator
GKOS
NEA
Relative Strength Index (RSI) 76.25 52.12
Support Level $105.88 $11.45
Resistance Level $116.72 $11.65
Average True Range (ATR) 3.24 0.09
MACD 0.06 -0.00
Stochastic Oscillator 93.18 51.08

Price Performance

Historical Comparison
GKOS
NEA

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About NEA Nuveen AMT-Free Quality Municipal Income Fund of Beneficial Interest Par Value $.01

Nuveen AMT-Free Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and the alternative minimum tax applicable to individuals, by investing in an actively managed portfolio of tax-exempt municipal securities. The company invest in Transportation, Utilities, Healthcare, Education and Civics, and other sectors, with maximum investment in Transportation.

Share on Social Networks: